Screener
Fulgent Genetics, Inc. FLGT Therapeutic Development — Operating Income
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 7:08 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-199065
| Three Months Ended March 31, 2026 | Laboratory Services | Therapeutic Development | Total |
|---|---|---|---|
| Revenue | $71,051 | $87 | $71,138 |
| Less: | |||
| Adjusted cost of revenue | 48,179 | 8 | 48,187 |
| Adjusted research and development | 6,461 | 4,178 | 10,639 |
| Adjusted selling and marketing | 11,576 | — | 11,576 |
| Adjusted general and administrative | 20,052 | 357 | 20,409 |
| Total adjusted operating loss | $(15,217) | $(4,456) | $(19,673) |
Item 1. Financial Statements.
FAQ
- What is Fulgent Genetics, Inc.'s therapeutic development — operating income?
- Fulgent Genetics, Inc. (FLGT) reported therapeutic development — operating income of -$4.46M in Q1 2026.
- How has Fulgent Genetics, Inc.'s therapeutic development — operating income changed year-over-year?
- Fulgent Genetics, Inc.'s therapeutic development — operating income decreased by 4.8% year-over-year, from -$4.25M to -$4.46M.
- What does therapeutic development — operating income mean?
- This is the net result of the therapeutic development segment's operations, calculated by subtracting operating expenses from segment revenue. It serves as the primary measure of the segment's operational profitability and financial performance.
Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — operating income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude